We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.14 | 2.10 | 2.18 | 2.20 | 2.19 | 2.19 | 604,698 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.93 | 7.33M |
TIDMIMM
RNS Number : 5794U
Immupharma PLC
01 April 2019
1 April 2019
ImmuPharma PLC
("ImmuPharma" or the "Company")
UPDATE ON NUCANT CANCER PROGRAMME
Clinical Development Collaboration with Incanthera
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update in relation to its discussions with Incanthera Limited ("Incanthera") on its Nucant cancer programme.
Background
On 7 September 2018, ImmuPharma announced that it had signed Heads of Terms with Incanthera, a specialist oncology company, and that it had invested GBP2m into Incanthera for a (circa.) 16% shareholding.
In addition, ImmuPharma granted Incanthera a period of exclusivity until 31 December 2018, during which it was expected to finalise the terms of a Definitive Licence Agreement for the Nucant technology. In consideration for this exclusivity period, ImmuPharma was granted warrants to subscribe for 363,637 ordinary shares in Incanthera at any time over a period of 5 years. The warrants have an exercise price of GBP5.50 per share, for an aggregate exercise value of GBP2 million. The terms of the Definitive Licence Agreement were expected to include, inter alia, (i) Incanthera paying a licence payment to ImmuPharma of GBP1m, with this payment to be made via the issuance of new ordinary shares in Incanthera; (ii) that Incanthera will be responsible for all of the development costs for the Nucant programme; and (iii) all future commercialisation revenues will be shared equally between the two companies.
A subsequent announcement on 31 December 2018 extended the exclusivity period to 31 March 2019.
The Company and Incanthera have to date not concluded the Definitive Licence Agreement. The exclusivity period has now expired and ImmuPharma is free, should it wish, to discuss collaborations with other parties for the Nucant cancer programme. Notwithstanding the expiry of the exclusivity period, discussions with Incanthera are continuing in good faith for a broader collaboration.
There can be no guarantee that any agreement will be reached with Incanthera on a broader collaboration.
If an agreement is reached, the Company will make a further announcement.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact: ImmuPharma plc (www.immupharma.com) + 44 (0) 207 152 4080 Dimitri Dimitriou, Chief Executive Officer Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin +44 (0) 203 368 8974 Vassil Kirtchev Stanford Capital Partners (Joint Broker) Patrick Claridge, John Howes +44 (0) 203 815 8880 SI Capital (Joint Broker) Nick Emerson +44 (0) 1483 413500
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCZMGFFLMGGLZM
(END) Dow Jones Newswires
April 01, 2019 02:00 ET (06:00 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions